The oldest, registered under NCT01404702, commenced in 2011 and investigated the stimulating effect of zoledronic acid (ZOL) therapy combined with interleukin-2 (IL-2) on γδ T cells capable of killing neuroblastoma cells in a pediatric group. Here, IL2 is linked to neuroblastoma.